Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information-Reference-Cited by-同舟云学术

Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information

Published:2021-05-10 Issue:7 Volume:63 Page:1476-1492
ISSN:0323-3847
Container-title:Biometrical Journal
language:en
Short-container-title:Biometrical Journal

Author:

Zhang Yuzi¹,Kutner Michael¹,Chen Zhengjia²³^ORCID

Affiliation:

1. Department of Biostatistics and Bioinformatics Emory University Atlanta GA USA

2. Division of Epidemiology and Biostatistics, School of Public Health University of Illinois at Chicago Chicago IL USA

3. Biostatistics Shared Resource Core University of Illinois Cancer Institute Chicago IL USA

Publisher

Wiley

Subject

Statistics, Probability and Uncertainty,General Medicine,Statistics and Probability

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/bimj.202000142

Reference26 articles.

1. Cancer phase I clinical trials: efficient dose escalation with overdose control

2. Dose-Finding Based on Multiple Toxicities in a Soft Tissue Sarcoma Trial

3. A novel toxicity scoring system treating toxicity response as a quasi-continuous variable in Phase I clinical trials

4. Adaptive Estimation of Personalized Maximum Tolerated Dose in Cancer Phase I Clinical Trials Based on All Toxicities and Individual Genomic Profile

5. Dose escalation with overdose control using a quasi-continuous toxicity score in cancer Phase I clinical trials

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quasi-partial order continual reassessment method: Applying toxicity scores to cancer dose-finding drug combination trials;Contemporary Clinical Trials;2023-02